Evaluating Regorafenib/Pembrolizumab in Refractory MSS-CRC
Afsaneh Barzi, Md, PhD, provides background on a new phase 1/2 studying exploring the combination of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer.
Afsaneh Barzi, MD, PhD, director, Employer Strategy (AccessHope); associate professor, Department of Medical Oncology & Therapeutics Research at City of Hope, explained the rationale for the phase 1/2 study of regorafenib and pembrolizumab in patients with refractory microsatellite stable colorectal cancer (MSS-CRC).
Transcription:
0:08 | In patients with microsatellite stable colorectal cancer immunotherapy has not been shown to be beneficial or effective. And therefore there is a search for appropriate combinations that can make basically the patients or the two more sensitive to immunotherapy.
0:27 | One of the combinations that has been high on the list is the combination of VEGF inhibitors and immunotherapy. Regorafenib is a multi-kinase inhibitor with a significant effect on VEGF or two which is a receptor to and given that it has single-agent activity in colorectal cancer. It seems like a very promising combination to look at the regorafenib plus pembrolizumab as a potential mechanism to overcome the resistance to pembrolizumab alone in patients with MSS colorectal cancer.
